Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical-stage biotechnology company dedicated to developing interleukin-1 beta (IL-1β) based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody designed to inhibit IL-1β and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Avalo Therapeutics, Inc. does
In the company’s own words
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical-stage biotechnology company dedicated to developing interleukin-1 beta (IL-1β) based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody designed to inhibit IL-1β and block downstream inflammatory pathways. Abdakibart is currently in Phase 2 clinical development for hidradenitis suppurativa (HS), a chronic, progressive inflammatory skin disease affecting an estimated 3.4 million people in the United States. The company expects to report topline data from its Phase 2 LOTUS trial in the second quarter of 2026 and is preparing for anticipated Phase 3 trials.
Avalo obtained rights to abdakibart through its acquisition of AlmataBio in the first quarter of 2024, which included worldwide exclusive licensing rights from Eli Lilly and Company. The company is subject to development and sales-based milestone payments to Lilly aggregating up to $720 million, as well as royalties between 5 and 15 percent of net sales upon commercialization. The composition-of-matter patent for abdakibart expired in February 2026, and the company plans to rely primarily on biologics regulatory exclusivity, which provides twelve years of protection from FDA approval in the United States and nine to eleven years in Europe.
Beyond abdakibart, Avalo maintains a pipeline of legacy programs including quisovalimab (AVTX-002), a monoclonal antibody targeting LIGHT, and several preclinical and early-stage assets. The company does not operate manufacturing facilities and relies on third-party contract development and manufacturing organizations for all biologic production. Avalo has limited sales and marketing infrastructure and anticipates developing these capabilities internally or through partnerships as products advance toward commercialization. The company faces intense competition from established pharmaceutical companies and other biotechnology firms developing IL-1β inhibitors and alternative treatments for inflammatory diseases. More information is available at www.avalotherapeutics.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WAYNE, PA
- Fiscal year end
- December
- CIK
- 1534120
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Avalo Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Avalo Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Avalo Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Avalo Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Avalo Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”